Oruka Therapeutics, Inc. (ORKA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Oruka Therapeutics, Inc. (ORKA) has a cash flow conversion efficiency ratio of -0.030x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-33.15 Million) by net assets ($1.11 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Oruka Therapeutics, Inc. market cap and net worth for the company's overall valuation and market capitalisation.
Oruka Therapeutics, Inc. - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Oruka Therapeutics, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Oruka Therapeutics, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oruka Therapeutics, Inc. ranked by their cash flow conversion efficiency. See Oruka Therapeutics, Inc. (ORKA) debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rayonier Inc
NYSE:RYN
|
0.116x |
|
Chailease Holding Co Ltd
TW:5871
|
0.009x |
|
Liquidia Technologies Inc
NASDAQ:LQDA
|
0.411x |
|
Yapi ve Kredi Bankasi AS
IS:YKBNK
|
-0.472x |
|
Loar Holdings Inc.
NYSE:LOAR
|
0.022x |
|
MGIC Investment Corp
NYSE:MTG
|
0.037x |
|
Fastighets AB Balder (publ)
ST:BALD-B
|
0.001x |
|
Credit Acceptance Corporation
NASDAQ:CACC
|
0.195x |
Annual Cash Flow Conversion Efficiency for Oruka Therapeutics, Inc. (2005–2025)
The table below shows the annual cash flow conversion efficiency of Oruka Therapeutics, Inc. from 2005 to 2025. View Oruka Therapeutics, Inc. share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $471.93 Million | $-88.21 Million | -0.187x | -23.52% |
| 2024-12-31 | $382.22 Million | $-57.84 Million | -0.151x | +42.21% |
| 2022-12-31 | $41.67 Million | $-10.91 Million | -0.262x | +28.76% |
| 2021-12-31 | $51.04 Million | $-18.76 Million | -0.368x | -121.36% |
| 2020-12-31 | $46.52 Million | $-7.72 Million | -0.166x | +73.68% |
| 2019-12-31 | $7.61 Million | $-4.80 Million | -0.631x | +53.84% |
| 2018-12-31 | $6.03 Million | $-8.24 Million | -1.367x | +19.63% |
| 2017-12-31 | $10.28 Million | $-17.47 Million | -1.700x | -151.82% |
| 2016-12-31 | $22.19 Million | $-14.99 Million | -0.675x | -144.04% |
| 2015-12-31 | $38.07 Million | $-10.53 Million | -0.277x | +56.64% |
| 2014-12-31 | $14.74 Million | $-9.41 Million | -0.638x | -88.01% |
| 2013-12-31 | $15.58 Million | $-5.29 Million | -0.339x | +75.81% |
| 2012-12-31 | $2.91 Million | $-4.08 Million | -1.403x | -15.55% |
| 2011-12-31 | $5.73 Million | $-6.96 Million | -1.214x | +1.24% |
| 2010-12-31 | $6.77 Million | $-8.32 Million | -1.229x | +78.16% |
| 2009-12-31 | $7.41 Million | $-41.73 Million | -5.630x | -262.54% |
| 2008-12-31 | $-5.31 Million | $-18.40 Million | 3.463x | +609.88% |
| 2007-12-31 | $67.66 Million | $-45.96 Million | -0.679x | -28.01% |
| 2006-12-31 | $69.84 Million | $-37.06 Million | -0.531x | +48.98% |
| 2005-12-31 | $56.76 Million | $-59.03 Million | -1.040x | -- |
About Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-… Read more